AMP: Annual Meeting & Expo 2026

We're excited to back at the AMP 2026 Annual Meeting!

Visit us at booth #437 to meet our team and discover how our innovative genomic solutions are helping laboratories streamline workflows, generate high-quality results, and gain confidence in molecular and cytogenetic testing. Explore the latest developments across our SureSeq™ NGS panels and CytoCell^® FISH probe portfolio, designed to support accurate, reliable genomic analysis in hematological and constitutional applications.

Corporate workshops

Attend our Corporate Workshop presentations on Wednesday, Nov 11 to hear about the real world applications of our latest MRD solutions.

Lessons learned: Evaluating ultra-high sensitive NGS in the future of AML MRD testing 

12pm-12:50pm

Skagit 3, Lower Level, Arch at 800 Pike

Presented by: Sean Glenn, PhD Roswell Park Cancer Institute

The rise of NGS-based MRD technologies provides a major advantage over current hemato-oncology methods by enabling both enhanced sensitivity in detection and more comprehensive genomic insights. Hear from Dr. Sean Glenn, Roswell Park Cancer Institute, as he shares his insights using the SureSeq™ Myeloid MRD Plus NGS Panel* in an expanded second phase retrospective cohort study of research specimens collected from patients undergoing AML treatment. 

*Research Use Only; Not for Use in Diagnostic Procedures

Add event to calendar

See more, sooner: Integrated NGS for deeper hematologic insights

2pm-2:50pm

Skagit 3, Lower Level, Arch at 800 Pike

Presented by:

• Dr. José-Mario Capo-Chichi, Clinical Molecular Geneticist-Toronto General Hospital
• Dr. Graeme Quest, Hematopathologist, Director of Histocompatibility and Immunodiagnostics – Kingston Health Sciences Centre

Join Dr. Graeme Quest, Kingston Health Sciences Centre, and Dr. José-Mario Capo-Chichi, Toronto General Hospital, as they evaluate the combined power of the SureSeq Myeloid Fusion NGS Panel* and a SureSeq myPanel™ NGS Custom Cancer Panel*.

See how this fusion panel’s targeted RNA-based, partner agnostic approach enables simultaneous interrogation of bait fusion targets and driver genes with multiple fusion partners. Partnered with the user designed targets, this custom solution consolidates multiple tests into a streamlined workflow, evolving with your lab’s needs. With highly sensitive CNV and SNV detection, faster turnaround time, and optimized target cover, this integrated end-to-end solution delivers deeper genomic insights in hematologic malignancies.

*Research Use Only; Not for Use in Diagnostic Procedures 

Add event to calendar